Zymeworks re­moves CFO; Gilead ex­tends Nurix deal

Plus, news about On­cono­va Ther­a­peu­tics, Trawsfyny­dd Ther­a­peu­tics, No­cion Ther­a­peu­tics, Gink­go Bioworks and Mod­u­lus Ther­a­peu­tics:

Zymeworks ousts CFO: The biotech dis­closed Mon­day that it had re­moved CFO Christo­pher As­tle on March 31, though did not pro­vide a rea­son in an SEC fil­ing. Pres­i­dent and CEO Ken­neth Gal­braith is serv­ing as in­ter­im CFO un­til the com­pa­ny finds a re­place­ment. “Fol­low­ing care­ful con­sid­er­a­tion, and in the in­ter­est of our com­mit­ment to con­tin­u­ing our growth and suc­cess, the de­ci­sion was made to ini­ti­ate a search for a new CFO who pos­sess­es the spe­cif­ic ex­pe­ri­ence, ex­per­tise and vi­sion to dri­ve our busi­ness strate­gies for­ward ef­fec­tive­ly,” a spokesper­son wrote to End­points in an email. The com­pa­ny’s shares $ZYME fell about 4% on Tues­day. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER